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ABSTRACT 
Of the seven existing classes of serotonin receptors, the 5-HT7 receptors (5-HT7Rs) are 
the most recently discovered.  Abundance of 5-HT7 in the central nervous system is suggestive of 
the receptor’s role in several physiological and pathophysiological functions.  Existing research 
has afforded a number of compounds exhibiting specific affinity to the receptor.  These selective 
ligands can provide structural information  about the  receptor and  can serve as the foundation 
for pharmacological profiling .  This thesis describes the synthesis of substituted pyrimidines and 
pyridines for affinity to the 5-HT7 receptor.  Organometallic species are the cornerstone for sev-
eral of the synthetic pathways. 
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1 INTRODUCTION  
Since the isolation of 5-hydroxytryptamine (5-HT) or serotonin (Figure 1) more than fifty 
years ago, countless biological assays have affirmed its influence throughout the human anato-
my.
1
  The biogenic amine is associated with an array of physiological processes including glu-
cose metabolism in the liver and cardio valvular operations as well as those of the central nerv-
ous system.
2,1
 Studies have implicated cerebral serotonin in the regulation of sleep, mood, ther-
moregulation, feeding, pain-perception, learning, memory, and arousal.
3,4
   Its functions are ac-
complished through the activation of a large family of specific receptors. Of the seven classifica-
tions of these receptors, the 5-HT7 subtype is the most recently unearthed and its function the 
most unclear.  For thorough understanding of the 5-HT7 receptor, the development of highly se-
lective ligands is imperative to determining its biological significance.  
 
N
H
NH2HO
 
1  
5-hydroxytryptamine (5-HT) 
 
1.1 Overview of Serotonin 
Once known as enteramine, serotonin was first detected within the cells of rodent intes-
tine where it regulates smooth muscle contractions.
4
 Although discovered in nonneural tissues, 5-
HT is significantly distributed throughout the central nervous system (CNS) of vertebrates and 
invertebrates alike.  In humans, serotonin-containing neurons are situated primarily within the 
2 
 
raphe nuclei of the midbrain.
4,5
  From each nucleus, serotonergic neurons project to multiple re-
gions of the CNS including the forebrain, brainstem, cerebellum and spinal cord.
5,6 
The two-step 
biosynthetic pathway of serotonin features a sequential hydroxylation and decarboxylation of the 
amino acid tryptophan.
4 
Once packed into vesicles, 5-HT is released into the synapse.  A trans-
membrane protein, the 5-HT transporter (5-HTT or SERT) modulates neurotransmission by re-
moving 5-HT from the synaptic cleft for either reuptake into synaptic vesicles for re-release or 
metabolic degradation by monoamine oxidase A (MAO-A).
6
   
The structural semblance of 5-HT with the hallucinogenic agent (+)-lysergic acid diethy-
lamide (2, LSD), discovered shortly before, suggested the association of serotonin with the me-
chanism of psychoactive substances.  Moreover, this 5-HT might be linked to psychological dis-
orders.  Intensive studies have since implicated dysregulation of the 5-HT system in the onset of 
a number of CNS disorders.
6
  
NN
O
H
 
2  
Lysergic acid diethylamide (LSD) 
These studies focused upon the direct and indirect assays of neurotransmitter function; the treat-
ment efficacy of agents affecting 5-HT function; and, the manipulation of the availability of 5-
HT by removing tryptophan.
6
 Accordingly, therapeutic agents affecting the 5-HT system have 
gained wide use in the treatment of CNS disorders.
4,6,7  
Selective serotonin reuptake inhibitors 
(SSRIs) competitively bind to serotonin transporters, thereby hindering the reuptake of the neu-
rotransmitter.
8
 SSRIs, such as the tricyclic fluoxetine (Prozac) or the atypical sertraline (Zoloft), 
3 
 
are widely employed as pharmacological treatments for depression and other illnesses including 
anxiety, schizophrenia, and panic disorders.   Monoamine oxidase inhibitors (MAOIs) also in-
duce an elevated amount of serotonin in the synapse and thus reduce neurotransmitter activity. 
MAOIs likewise elicit an antidepressant response and have long been employed in pharmacolog-
ical depression therapies.
6,7
  
1.2 Receptors to Serotonin (5-HT) 
The physiological and pathological influence of serotonin is attributed to the neurotrans-
mitter’s activation of at least fourteen distinct receptors.  These receptors are categorized based 
on structure (amino acid sequence homology), operation (pharmacology), and signal transduction 
pathways into seven families 5-HT1 through 5-HT7.
9
   The receptors belong to the superfamily of 
G protein coupled receptors (GPCRs), with the exception of the 5-HT3 receptor class.  Subdi-
vided into 5-HT3A and 5-HT3B, these receptors are ligand-gated ion channels.
8
    
Representing a large family of transmembrane proteins, GPCRs modulate the transmis-
sion of extracellular chemical signals.  Associated with guanosine triphosphate (GTP), they 
modulate signal transduction pathways, such as that of cyclic adenosine monophosphate 
(cAMP), eliciting cellular responses.
10 
The 5-HT GPCRs are comprised of seven trans-membrane 
(TM) helices that form an anticlockwise helix bundle.  These GPCR feature a single amine 
bound to an aromatic ring by a two carbon chain and include all 5-HT receptors, except 5-HT3 
subtype as noted.  GPCR signal transmission is effected through the rearrangement of the trans-
membrane domains to expose the G-protein binding site at the interior.  This rearrangement may 
occur spontaneously or proceed from small molecule or peptide binding in the interior of the 
transmembrane bundle.
9
  Accordingly, these receptors have been the target of binding studies to 
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evaluate physiological influence.  Ligand-receptor binding assays are performed to provide struc-
tural and functional information for potential pharmacological use.  
The earliest identified receptors, 5-HT1 and 5-HT2, emerged out of radioligand assays on 
5-HT and the structurally comparable LSD 2.  The results suggested that serotonin and the hallu-
cinogen functioned via the same receptor.  So began the development of selective 5-HT antagon-
ists as radioligands for studying serotonergic receptors.  It was found that a tritiated analog of 
spiperone 3, a dopamine ligand, demonstrated affinity for non-dopaminergic sites at which tri-
tiated 5-HT also displayed affinity.  Subsequent assays concluded that [
3
H]spiperone and [
3
H]5-
HT labeled two distinctive binding sites, later termed  5-HT1 and 5-HT2.  Shortly thereafter, 5-
HT1A, 5-HT1B, 5-HT2, and 5-HT3 receptors were identified.
8
  Receptor classifications and mole-
cular cloning experiments expanded the family to include more subtype populations, the 5-HT4 
receptor, and the higher end receptors 5-HT5, 5-HT6, and 5-HT7 of the late 1980s and the 1990s.
8
     
O
F
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1.3 The 5-HT7 Receptor 
First cloned in 1993, the 5-HT7 receptor family has been positively identified in a number 
of species including guinea pig, mouse, rat, pig, and human.
 12
  Most recently, the receptor has 
been cloned from members of the arthropoda and the nematoda phyla.   
As a member of the GPCR family, the 5-HT7 receptor is positively coupled to adenylate 
cyclase and activates extracellular signal-regulated kinase (ERK).  It has recently been estab-
5 
 
lished that the 5-HT7 receptor is also coupled to a G12-protein through which it activates small 
GTPases. 
13,14
 Nonetheless, the 5-HT7 receptors demonstrate a low overall amino acid homology 
(~40%) with the other G-protein coupled serotonergic receptors.
9
  
Alternative splicing of the receptor mRNA has resulted in four isoforms in rat and human 
tissues, i.e., 5-HT7 (a), (b), (c) in rats and 5-HT7 (a), (b), (d) in humans.
13
  The isoforms, differing only in 
length and amino acid composition at the carboxyl terminal, exhibit a high degree of interspecies 
amino acid homology (~ 95%).
9,13
     These isoforms also demonstrate comparable pharmacolog-
ical attributes, signal transduction pathways, and tissue distributions.
13
 For the human variants, 
the gene encoding 5-HT7 is located on chromosome 10q23.3-q24.4 with the most abundant iso-
form 5-HT7(a) consisting of 445 amino acids.   
In situ hybridization and ligand binding approaches indicate the localization of 5-HT7 
throughout the peripheral and central nervous systems.
15
  In the periphery, 5-HT7 is found in the 
gastrointestinal tract, in skull blood vessels, and in vascular smooth muscle, as well as in the 
spleen, kidney, and within certain optic tissues.
13
 Messenger RNA distribution confirms that ce-
rebral 5-HT7 is abundant in the hippocampus, thalamus, hypothalamus, and cerebral cortex.
16
    
In the hypothalamus, the receptor is isolated in the suprachiasmatic area, a region associated with 
circadian rhythm regulation.
17
  This widespread distribution suggests the participation of 5-HT7 
in an array of physiological  processes. 
1.4 Ligands to the 5-HT7 Receptor 
The 5-HT7 receptor is characterized by high affinity for 5-HT (1), 5-carboxytryptamine 
(5-CT), 5-methoxytryptamine (5-MeOT), and methiothepin as well as a moderate affinity for 8-
OH-DPAT (Figure 1).
15
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Figure 1. 5-CT, 5-MeOT, methiothepin, and 8-OH-DPAT bind to the 5-HT7 receptor 
 
In the years following the positive characterization of the 5-HT7 receptors, binding assays 
afforded a number of non-selective ligands demonstrating high receptor affinity.  These agents 
typically behave as antagonists blocking the activity of the endogenous ligand 5-HT as well as 
other agonists.  Agonist binding at the 5-HT7 receptor  increases intracellular levels of cAMP.
18
 
Pittalá et al. describe several of these non-selective ligands and their classes: ergolines (including 
2-Br-LSD  and mesulergine), piperidine derivatives (including ritanserin, risperidone, and spipe-
rone 2), and aporphine derivatives (including R(3)-aporphine) as shown in Figure 2.
15
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Figure 2.  Several non-selective 5-HT7 ligands
15 
 
A number of psychoactive drugs have also demonstrated non-selective affinity to the 5-
HT7 receptor.
13
  These agents include the antipsychotic cyclic analogues clozapine, mianserin, 
and maprotiline, as well as a number of phenothiazines (including chlorpromazine) and thioxan-
thenes (including chlorprothixene), Figure 3.
13,15
   
8 
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Figure 3.  Psychoactive agents demonstrating non-selective 5-HT7 receptor affinity
13,15
 
 
The widespread distribution of  5-HT7 and the diverse array of agents exhibiting receptor 
affinity suggest a wealth of physiological functions for the receptor.  Efforts to elucidate the phy-
siology of the 5-HT7 receptor
 
rely upon the development of selective antagonists and agonists.  
Within the last two decades, a number of selective ligands to the 5-HT7 receptor have been de-
veloped and are representative of a diverse group of chemical compound classes. 
In the early 1990s, a highthroughput screening (HTS) of the SmithKline Beecham com-
pound bank against the human cloned 5-HT7 receptor provided 3 as a four-component diaste-
reomeric mixture (Figure 4).   Subsequent structural modifications and a series of structure-
activity-relationship (SAR) studies on the compound resulted in the reporting of the first selec-
9 
 
tive 5-HT7 antagonists.  Members of the arylsulfonamide class, SB-258719 (4, pKi = 7.5) and its 
pyrrolidine derivatives SB-269970 (5, pKi = 8.9) and SB-258741 (pKi = 8.5) demonstrated mod-
est 5-HT7 affinity as well as at least 100-fold selectivity over other serotonergic receptors.  Sub-
sequent analogues include SB-656104 (6, pKi = 8.7) and SB-691673 (7, pKi = 8.65).
15,19
  Origi-
nally deemed antagonists, recent biological assays have reported some level of inverse agonist 
activity for the three early arylsulfonamide ligands.  Inverse agonists bind to the receptor and de-
crease cAMP activation; SB-258719, is closest to a neutral antagonist, SB-258741 is a partial 
inverse agonist, and SB-269970 is a full inverse agonist at recombinant 5-HT7.
20 
10 
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Figure 4.  Selective 5-HT7 receptor ligands of the arylsulfonamide class
15,19 
 
Another major class of 5-HT7 ligands consists of the tetrahydrobenzindoles first reported 
in 1999.
21
  Kikuchi and coworkers under Meiji Seika Kaisha, Ltd., identified DR-4004 (8, pKi = 
8.67) as a potent 5-HT7 antagonist (Figure 5).
21 
 The (2-methoxyphenyl)piperazinyl derivatives 
11 
 
published in a later paper provided 9 (pKi = 8.29), an antagonist demonstrating  affinity at the 5-
HT7 receptor.
13
 Subsequent SAR studies expanded the class to include a number of fused-ring 
analogues.   These compounds, DR-4446 (10, pKi = 8.01), DR-4365 (11, pKi = 8.45), and DR-
4485 (12, pKi = 8.14), demonstrate significant affinity for the 5-HT7 receptor over other relevant 
serotonergic receptors like 5-HT2.  The halogenated derivative DR-4485 exhibits superior oral 
bioavailability.
15
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Figure 5.  The tetrahydrobenzindoles class of serotonin receptors 
 
12 
 
Patents filed in 1999 and 2000 contributed to pyridines and piperazines as emergent 
classes of 5-HT7 receptor ligands. With the identification of 13, pKi = 9.2 Shinogi et al. were 
first to report a pyridine derivative demonstrating agonist activity at 5-HT7 receptors.
15
 Parikh 
and coworkers at Pfizer Inc. introduced a series of 4-(pyridin-2-yl)piperazine derivatives as 5-
HT7 agonists.
22
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13 
Developed from a series of thiazoles and thiopyridines under Merck in 2004, compound 
14 (pKi = 9.22) exhibits high affinity and selectivity over other 5-HT receptors.
23
     
 
N S
N
 
14 
Also during 2004, Leopoldo et al. focused research efforts upon the influence of the 1-
arylpiperazine moieties in 5-HT7 ligands developed by Kikuchi and Parikh among others.  These 
efforts afforded a series of high affinity 5-HT7 receptor ligands based on N-(1,2,3,4,-
tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamide structures.
24
  Structural modifications, 
including variations in alkyl chain length and aromatic substitution linked to the N-1 piperazine 
ring, provided several high affinity compounds.  From these 1-(2-methoxyphenyl)piperazine de-
rivatives, namely 14 (pKi = 7.94), compounds 15 (pKi = 8.38) and  16 (pKi = 9.66) were devel-
13 
 
oped and are presented in Figure 6.  The hydroxy-substituted 14 (LP-44) is a potent 5-HT7 re-
ceptor putative agonist with selectivity over 5-HT1a and 5-HT2a receptors; 16 is a selective anta-
gonist.
24
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 14      15      16 
Figure 6.  1-(2-methoxyphenyl)piperazine derivatives demonstrating agonist to antagonist activi-
ties at the 5-HT7 receptor.
24 
 
Related to tetrahydrobenzindole family of 5-HT7 receptors are the structurally similar 
oxindole derivatives reported in 2008.
25
  The compounds feature an oxindole scaffold and long-
chain arylpiperazine.  The oxidinole structure is less rigid than the tetrahydrobenzindole skeleton 
resulting in decreased lipophilicity; this decrease is hoped to increase bioavailability for potential 
pharmacological use.  Several of these compounds demonstrated high affinity and proved to be 
highly potent antagonists.  Representatives of the series are 17 (pKi = 8.15) and 18 (pKi = 
9.10).
25 
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Yoon and coworkers report a series of 1-arylpiperazines developed as sulfonamide ana-
logs.  Piperazine derivatives based on the structure of SB-269970 were designed and evaluated 
against the human recombinant 5-HT7 serotonin receptor in 2008.  Of the series, 4-methoxy-N-
[3[(4-substituted phenylpiperazino)propyl]benzene sulfonamide 19 (IC50 = 37) demonstrates 
good activity and good selectivity over 5-HT1a, 5-HT2a, 5-HT2c, and 5-HT6 receptors.
26
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The development of diaminotriazine, diaminopyridine, and diaminopyrimidine 5-HT7 li-
gands prompted an investigation into the effect of nitrogen atom position and frequency on affin-
ity.  In 2004, researchers at Bristol-Myers Squibb Pharmaceuticals reported a series of amino-
triazines and aminopyridines exhibiting selective antagonist activity at the 5-HT7 receptor.
27
  The 
studies on the amino-azines led these researchers to examine receptor affinity with heteroaryl 
compounds of various nitrogen atom frequencies and positions.  Variation in the position of the 
15 
 
nitrogen in the ring significantly altered 5-HT7 binding affinity.  A series of diaminopyridines, 
diaminopyrimidines, and diaminotriazines demonstrating selective 5-HT7 receptor affinity were 
afforded.  Representative compounds are 21 (pKi = 8.4) and 22 (pKi = 8.7) as shown in Figure 
7.
28 
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Figure 7.  Diaminopyridine and diaminotriazine compounds demonstrating selective activity to 
the 5-HT7 receptor.
28
  
 
While piperazines and sulfonamides make up a large class of selective ligands to the 5-
HT7 receptor, receptor ligands come from an array of chemical families.  As research into novel 
selective ligands has continued, diversity among the chemical classes exhibiting selective affinity 
has likewise expanded.  Many compounds of the aporphine family function as selective ligands 
to several of the serotonergic receptors.  A 5-HT7 selective aporphine derivative was developed 
from  modifications performed on R-(3)-aporphine (Figure 3).  These modifications focused on 
altering  the substitution pattern in C11 of the phenyl ring; several different ortho substituents 
were introduced.  These derivatizations provided the highly selective and potent atropisomeric 
biaryl aporphine derivatives 23 (pKi = 8.42) and 24 (pKi = 7.42) shown in Figure 8.
29
   The 
aporphines functioned as antagonists and inhibited 5-HT stimulation of cAMP.
29
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Figure 8.  Aporphine derivatives demonstrating affinity to the 5-HT7 receptor.
29 
 
Holmberg and coworkers reported the selectivity of a series of 8-substituted-3-
aminochromans (3,4-dihydro-2H-1-benzopyrans) and 2-aminotetralins in 2004 and 2005.  Bind-
ing to 5-HT7 of these structures was found to be stereospecific; (S)-tetralin and (R)-chromans are 
the favored enantiomers.
30
  The reported ligands exhibit activity at the 5-HT7  receptor ranging 
from  antagonist to full agonist.  A few of the compounds demonstrate high selectivity over other 
receptors.  Derived from the series is a putative selective receptor agonist, 25, AS-19, Figure 9.
31 
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Figure 9.  Aminochroman and aminotetralin derivatives.
30, 15
    
 
Several reports and filed patents have also featured the synthesis of quinolines, pyrro-
lidnes, and aminoalkyl sulfones as selective, high affinity 5-HT7 receptor ligands.    More recent 
papers and patents have included benzimiadazolone as well as other quinoline and piperazine 
derivatives.
32,33
  A selection of these compounds is presented in Figure 10 with their respective 
pKi values.    
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Figure 10.  Several compounds displaying 5-HT7 receptor selectivity and affinity. 
 
1.5 The 5-HT7 Receptor and Physiological Processes 
The affinity of 5-HT7 for several psychoactive agents coupled to its cerebral localization 
has generated substantial research into the role of the receptor in neurological disorders such as 
depression and anxiety.  Indeed, during the past decade the receptor has been associated with a 
number of physiological processes within the central nervous system as well as in the periphery.  
Pharmacological agents and/or knockout mice (in which functional 5-HT7 receptors are absent) 
are used in animal behavioral models devised to simulate human disorders.
5
   Deviant behaviors 
are indicative of a neurological disorder.  Multiple behavioral assays have indicated an anti-
19 
 
anxiety effect for SB-269970, the selective ligand originally classified as a 5-HT7 selective anta-
gonist.
3,5,15
   
Early on, these behavioral models also  revealed the significance of 5-HT7 in the supra-
chiasmatic nucleus (SCN), a brain region associated with the circadian biological clock, sleep, 
and mood.  Pharmacological profiling, again with SB-269970, confirmed that the 5-HT7 receptor 
mediates 8-OH-DPAT-induced phase resetting within the SCN.  Phase-setting tempers the sleep 
pattern according to periods of day and night.  The antidepressant-like activity, altered sleep pat-
terns, and light/dark immobility observed in these studies highlight the effect of 5-HT7 on the 
SCN.
15 
 
In behavioral models used in the assessment of antidepressants, 5-HT7 receptor blockage 
or receptor gene inactivation produces antidepressant behavior.  Concurrent administration of 
SB-269970 with antidepressants has elicited antidepressant activity in several behavioral tests.
3,5
 
Fittingly, it has been suggested that the affinity of various antidepressants (presented in Figure 4) 
for the 5-HT7 receptor is the driving force behind their physiological function.
5
  The high affini-
ties of clozapine and risperidone (Figure 4) for the receptor established the link between 5-HT7 
and schizophrenia shortly after the introduction of the 5-HT7 receptor class.  More recently, the 
atypical antipsychotics and established antidepressants, amisulpride and aripiprazole have dem-
onstrated high affinity for the 5-HT7 receptor.
15,34
   
Several other physiological operations are associated, to an extent, with the 5-HT7 recep-
tor.  Obsessive compulsive disorder (OCD), epilepsy, migraine, thermoreguation, and certain 
cognitive functions have also been linked to the receptor.
24
 For OCD, typified by obsessive 
thoughts and repetitive or specific behavior, treatment is often a selective serotonin reuptake in-
hibitors (SSRI) antidepressant.  Interestingly, behavioral model testing has shown that 5-
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HT7receptor antagonism using SB-269970, or through receptor gene inactivation, decreases the 
occurrence of compulsive behavior.
5
  The elevated abundance of 5-HT7 in the thalamus has been 
suggestive of a role of the 5-HT7 receptor in epilepsy, a neurological disorder that induces sud-
den seizures.  It was found that the selective 5-HT7 antagonist SB-269970 reduced unprompted 
epileptic activity in rats.
23, 25
  Cranial vasodiation, associated with migraines, is regulated by se-
rotonin which in turn is regulated by 5-HT7 among the other 5-HT receptors.  Nonetheless, as 
was observed with antidepressents, several anti-migraine drugs exhibit moderate to high affinity 
at the 5-HT7 receptor.
34
  Gargaglioni and coworkers established the relationship between 5-HT7 
and thermoregulation using SB-269970.  The 5-HT7 receptor was shown to regulate hypothermia 
occurring from reduced oxygen content.
15
 Cifariello et al. at the University of L’Aquila in Italy 
report the influence of 5-HT7 receptor in learning and memory.  Administration of SB-269970 to 
lab mice improved memory in multiple behavioral tests.
3
 
Motor activity of the gastrointestinal tract and bladder function have also both been asso-
ciated with the receptor.  Stimulation of neuronal 5-HT7 receptors produced muscle relaxation in 
pig small intestine.  Subsequent research has sought to elucidate the influence of 5-HT7 in ga-
strointestinal disorders such as irritable bowel syndrome.    The 5-HT7 receptor has recently been 
linked to an excitatory physiological role in the control of bladder function.  Selective ligand SB-
269970 increased bladder pressure and volume, ultimately eliminating the impulse to urinate.
15
 
1.6 The Pharmacophore Model 
 The multitude of chemical families that contribute to the library of selective 5-HT7 recep-
tor ligands thwarts immediate recognition of the structural aspects that promote ligand-receptor 
interaction.   Identification of these structural features is essential to uncovering the tertiary 
structure of the receptor.  Furthermore, at present there is no X-ray crystallography structure 
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available for the 5-HT7 receptor.  A  computer generated 3-dimensional  pharmacophore model 
highlighting these structural aspects can be used to predict affinity among structurally similar 
compounds;  to facilitate the design and synthesis of novel ligands; and to fully assess the physi-
ological functions of the receptor.  Ultimately these efforts will advance the clinical applications 
associated with the 5-HT7 receptor. 
 Lopez-Rodriguez established the first pharmacophoric hypothesis for 5-HT7 receptor an-
tagonism in 2000.
35
  These early efforts provided a minimal list of the structural requirements for 
5-HT7 receptor nonselective antagonism: an aromatic ring, a basic nitrogen atom (positive 
charged center, PI), a H-bonding acceptor group (HBA), and a hydrophobic region (HYD) at 4.9 
– 5.9 A apart from the basic nitrogen center.      
Later in 2004, the same group reported an optimization and validation of their former 
model to incorporate the several new selective 5-HT7 receptor antagonists that had since been 
developed.  Using a series naptholactam and napthosultam derivatives, the researchers formu-
lated an updated model and revised the essential structural requirements.
15,36
  According to the 
revised model, a basic nitrogen atom (positive charged center, PI), a H-bonding acceptor group 
(HBA), and three hydrophobic regions (HYD) at the distances presented in Figure 11 below are 
necessary.
36
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Figure 11.   A revised molecular model of 5-HT7 antagonism (blue, HYD; red, PI ; green, 
HBA)
36 
 
 A conformational analysis of the selected ligands bound at the transmembrane domain of 
the 5-HT7 receptor was performed.  This afforded a pharmacophoric model in which the most 
favorable (high affinity) naptholactam or napthosultam compounds featured a spacer of an op-
timal chain length.
36
 The 3D model revealed how the ligands bind to the amino acid residues of 
the transmembrane binding site of the 5-HT7.  According to the model, the HBA feature of the 
ligand interacts with the hydroxyl groups of serine and threonine; the HYD1 feature binds phe-
nylalanine via aromatic interaction, the PI moiety forms an ionic bond or salt bridge with an as-
partic acid residue; and the HYD3 region interacts with aromatic residues phenylalanine and ty-
rosine of the binding site via π- π interaction.36 
Kolaczkowski and Bojarski et al. also report two novel 5-HT7 antagonism pharmaco-
phores based on direct ligand-receptor interaction of thirty-one receptor antagonists. 
40
  The two 
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proposed models describe the structural features required for affinity and those required for se-
lectivity.  The affinity model, formulated using nonselective ligands, outlines six structural fea-
tures of the ligand structure that promote general ligand-receptor interaction: a PI, three hydro-
phobic/aromatic regions (HYD/AR1-3), and two hydrogen bond acceptors (HBA1 and HBA2).  
Affinity to 5-HT7 receptor requires at least three of these components aligned in a specific spatial 
arrangement.  According to the selectivity pharmacophore, only three features are essential for 
selective affinity.  A PI and AR1 at 6.9 -7.7 Å apart are required.  They propose that the AR1 
must be specifically aligned to promote an aromatic π-π stacking with phenylalanine or an ion- π 
interaction with arginine in the binding site. Figure 12 presents a summary of the essential struc-
tural features for affinity and selectivity and the respective distances between each moiety.
15,40
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    PI HYD/AR1 HYD/AR2 HYD/AR3 
HYD/AR1 6.9 – 9.4    
HYD/AR2 4.3 – 7.8 11.1 – 14.4   
HYD/AR3 3.7 – 6.1 8.75 4.1 – 4.8  
HBA1 3.7 – 5.1 3.7 – 3.8 8.3 – 10.1 6.9 
HBA2 5.1 – 6.9 14.2 2.8 – 3.7 2.8 – 3.7 
(a) 
 
    PI HYD/AR1 HYD/AR2 
HYD/AR1 6.9 – 7.7   
HYD/AR2 4.3 – 7.0 11.1 – 13.2  
HBA1 3.7 – 5.1 3.7 – 3.8 8.3 -10.1 
(b) 
Figure 12.  Pharmacophore model for affinity (a) and  for selectivity (b) with the respective dis-
tances (Ǻ) as proposed by Kolaczkowski et al .40 
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 Our research group has also developed a 3-D pharmacophore model for 5-HT7 receptor 
antagonism.  The generation of a 3-D computational model of the TM domain complexed with 
ligands of interest was achieved with SYBYL v8.1.   A series of substituted pyrimidine com-
pounds were prepared and assessed for inhibition of a radioligand at the 5-HT2a and the 5-HT7 
receptors.  According to the 3-D QSAR studies, the essential structural features are : a PI, a 
HBA, and two HYD regions.  Figure 13 depicts the hypothesized model and a representative 
compound, synthesized in our lab, which bears the essential structural aspects. 
 
HBA
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Figure 13.  Our pharmacophore model and a representative compound labeled accordingly 
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1.7 Overview of Pyrimidines and Pyridines 
Pyrimidines and pyridines have contributed to the diverse library of compounds demon-
strating selective affinity to the 5-HT7 receptor.  Novel diaminopyrimidines, diaminopyridines, 
and thiopyridines have been described.   Ligands synthesized in this thesis feature pyrimdine and 
pyridine moieties combined with piperazines, a prominent group among the compounds bran-
dishing selective affinity to the 5-HT7 receptor.  Specifically, these substituted pyrimidines and 
pyridines will contribute to the class of arylpiperazines, a major category of selective 5-HT7 re-
ceptor ligands. Preparation of novel, structurally diverse pyrimidine and pyridine analogs re-
quires a consideration of the structural features that govern their chemical reactivity.   
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Pyrimidine 
 
Pyrimidine is a prominent member of the diazine family of heterocyclics.  It is found 
throughout nature as a component of nucleic acids, nucleotides and corresponding nucleosides.  
Purines, comprised of fused pyrimidine and imidazole rings, are essential components of DNA 
and RNA.  The aromatic heterocycle is also widespread among pharmaceutical agents. Oxyge-
nated pyrimidines, or, barbituric acid derivatives, are commonly employed as therapeutic seda-
tives and antidepressants; several sulfa drugs including antibacterials, antihypertensives, and an-
tifolates feature a pyrimidine moiety.
44
 First isolated in 1899, the heterocycle has been extensive-
ly studied affording a wealth of information regarding its physical and chemical attributes.
45
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In pyrimidine, each of the four sp
2
 hybridized carbon atoms features a p orbital perpendi-
cular to the plane of the ring and each p orbital contains one pi electron.  The nitrogen atoms are 
likewise sp
2
 hybridized each containing one π electron in their p orbitals for a total of six π elec-
trons.  The lone pair electrons do not contribute to the aromatic π electron sextet.45    
N
N
N
N
lone pairs of electrons
pyrimidine
H
H H
H
 
Figure 14.  Orbital image of pyrimdine featuring lone pair electrons.
45
   
 
These unshared electrons at the two nitrogen atoms contribute to the low basicity of py-
rimidine (pKa = 1.3) compared to pyridine (pKa = 5.2), bearing a single imine nitrogen atom.  
The electronegative nitrogen atoms induce polarization in the sigma bond framework. The resul-
tant increase in electron deficiency at the 2, 4, and 6 positions makes these carbon atoms more 
susceptible to nucleophilic attack. This nucleophilic attack is especially feasible when a displa-
ceable halide is a substituent.
46
  For halo-diazines in which the halide is alpha or gamma to a ni-
trogen, nucleophilic displacements become even more facile.  The 2- and 4- halo-pyrimidines are 
particularly reactive because the anionic intermediates receive direct mesomeric stabilization 
from both imine nitrogen atoms, figure 15.
45
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Figure 15.  Mesomeric structures of pyrimidine.  The  positions 2,4, and 6 bear the positive 
charge.
45
   
 
These structural aspects are the foundation of the chemistry that drive the development of 
pyrimidine compounds of biological interest.  Pyrimidine compounds have been explored for use 
as histamine and adenosine receptor antagonists as well as among several other biological recep-
tors and modulators.
47,48
 As previously described, several diaminopyrimidines have been synthe-
sized for selective affinity at the 5-HT7  receptor.  Foregoing research efforts of our group have 
provided a series of substituted pyrimidines exhibiting affinity to the 5-HT2a receptor.  Functio-
nalization of the pyrimdine ring was achieved using organolithum reagents to supply aryl substi-
tuents at the positions 2 and 4 as well as a methylpiperazine moiety at position 6.  Heteroaryl 
substituents at postions 2 and 4 afforded the most effacicous ligands within the series.  A potent 
representative of these compounds is 28 (pKi 5-HT2a =  8.1).
49
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This work has been translated into the present investigations focusing upon the develop-
ment of substituted pyrimidine ligands for the 5-HT7 receptor.  The synthesis of the compounds 
we present incorporates a vinyl moiety that enables further derivatization and subsequent addi-
tion of methylpiperazine at the 2-position. 
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Pyridine 
Pyridine is a ubiquitous chemical compound.  The aromatic, monocyclic azine is utilized 
as a reagent or as a polar aprotic solvent.  It is salient in a number of biological systems and in-
dustrial applications.  Naturally occurring pyridines include the nicotinamides, a component of 
the vitamin B group.
46,47
  Pyridines are precursors to various pharmaceuticals, adhesives, agri-
chemicals, and synthetic pigments. 
46
    
The aromatic nitrogen heterocycle is closely related to benzene as it differs only by the 
replacement of one –CH unit with N.  The five carbon atoms are sp2 hybridized as is the nitrogen 
atom forming a delocalized π system extending as a closed loop above and below the plane of 
the ring.  The carbon-nitrogen bonds are slightly shorter than C-C bonds owing to the increased 
electronegativity of the nitrogen atom.  Consequently, the aromatic system is slightly distorted as 
electron density is concentrated at the N atom.  The nitrogen lone pair is not involved in the aro-
matic π electron system and instead contributes to the basicity of pyridine (pKa = 5.2).  
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Figure 16.  Orbital diagram of pyridine 
 
Polarized mesomeric contributors in which nitrogen is negatively charged illustrate the 
electron deficiency at positions 2, 4, and 6 of the ring, Figure 17.  These positions are the crux of 
the chemistry of pyridines.
45
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Figure 17.  Resonance contributors to pyridine structures.
45
   
 
As with the pyrimidines, these structural and electronic characteristics govern the chemi-
cal reactivity of pyridine.  Several patents have described the synthesis of pyridines as selective 
5-HT7 receptor agonists and antagonists.
50,51
 A recent report features the preparation of a series 
of 4,6-disubstituted 2-(4-methyl-1-piperazinyl) pyridines demonstrating selective affinity for the 
5-HT7 receptor over the 5-HT1a and 5-HT2a receptors.  Several of these analogs feature a hete-
roaryl substituents.  The synthetic pathway features ring formation via [3 + 3] annulation, a ben-
zotriazole-assisted Katrizky methodology.
52,53
 Our research also focuses upon the addition of a 
methyl piperazine substituent and heteroaryl groups to the pyridine ring.  However, we outline 
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methods incorporating direct C – C and C – N atom coupling on the pyridine ring via Suzuki 
coupling and Buchwald-Hartwig amination. 
2 RESULTS AND DISCUSSION 
2.1 Synthesis of Substituted Pyrimidines 
As described, a number of ligands to the 5-HT7 receptor featuring a pyrimidinyl moiety 
have been reported.  It is with this in mind that several functionalized pyrimidines have been de-
rived from the starting compound 2-chloropyrimidine.  
 
2.1.1 From 2-Chloropyrimidine 
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Scheme 1. 
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The reaction of a vinyllithium reagent with 2-chloropyrimidine at the C4=N3 bond is an 
efficient method for the addition of a vinyl moiety at position 4.
54
  In situ generated vinyllithium 
from the reaction of tetravinyltin with the tert-butyllithium reagent as reported by Strekowski et 
al.   Rearomatization of the resultant dihydro intermediate using the powerful oxidizing agent 
2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) is also reported and afforded  1, 2-chloro-4-
vinylpyrimdine in Scheme 1.
55
 
2.1.2 Nucleophilic Conjugate Addition 
The treatment of 2-chloro-4-vinylpyrimidine 1 with various nucleophiles in equimolar 
amount provided the 1,4 conjugate addition product, compounds 2 - 5.  Nuclear magnetic reson-
ance NMR analysis affirms that compounds 2 - 5 exhibit the characteristic pyrimidine doublet 
which represents the unsubstituted 5- and 6- position hydrogens of the aromatic ring with a 
coupling constant of approximately 5 Hz.  These compounds also bear two triplet peaks which 
correspond to the methylene hydrogens obtained in the conjugate addition product.  The addition 
of ethylamine yielded the single addition compound 2.  Triplet and quartet peak signals corres-
ponding to the methyl and methylene hydrogens, respectively, of the ethylamine group are also 
apparent at 1.10 and 2.69 ppm.    Resonance analysis of compound 3 features the characteristic 
pyrimidine peaks at 7.21 and 8.50 ppm as well as a singlet signal at 1.09 ppm corresponding to 
the hydrogens of the tert-butyl amine group.  Compound 4, the structural isomer of 3, displays 
the characteristic NMR signal pattern of a butyl group:  a triplet far peak downfield (0.91 ppm) 
corresponding to the three shielded methyl hydrogens;  multiplet peak signals at 1.33 and 1.46 
ppm representing the interior methylene groups; and a triplet further downfield 2.64 ppm for the 
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methylene group  nearest the electronegative N atom of the butyl moiety.  Analysis of the NMR 
spectrum  of 5 indicates the presence of pyrimdine as its characteristic peaks are apparent at 7.20 
and 7.49 ppm with a coupling constant of  5 Hz.  The –CH2- hydrogens are represented by the 
triplet peaks at 2.83 and 2.98 ppm.  The phenyl group hydrogens correspond to the multiplet sig-
nals, integrating to five hydrogens, evident at 6.85, 6.93, and 7.20 ppm. The spectrum also fea-
tures distinctive methyl piperazine signals; two triplet peaks at 2.68 and 3.20 corresponding to 
the four piperazinyl hydrogens.    
The addition of ethylamine  to 2 in 0.55 equivalents afforded a conjugate addition dimer 
product 6 as the major product obtained as shown in Scheme 2.  Characteristic pyrimidinyl pro-
ton  peak signals are apparent in the NMR spectrum of 6.  At 2.88 ppm, the doublet of triplet 
signals correspond to the eight methylene hydrogens forming the bridge between the two pyri-
mine rings.  Triplet and quartet peak signals corresponding to the –CH3 and -CH2- hydrogens, 
respectively, of the ethylamine group are also apparent at 1.00 and 2.58 ppm. 
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Scheme 2. 
 
For the addition of amine nucleophiles, conjugate addition across the vinyl group was 
preferred over substitution at the chlorine atom. The major product obtained from the addition of 
benzenethiolate, however, favored  displacement at the 2-chloro position (18 % yield) and di-
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addition with replacement of the chlorine atom as well as addition across the vinyl moiety as 
shown in Scheme 3.  Compound 7 is a  minor product and the diaddition compound 8 is pre-
ferred.  This occurrence is attributed to the increased nucleophilicity of the larger, more basic 
sulfur atom.   
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Scheme 3. 
 
Nucleophilic displacement of chloride in the 4-substituted 2-chloropyrmidines by treat-
ment with excess 1-methylpiperazine provides compounds 9 – 12 (Scheme 1).  The N-
methylpiperazine nucleophile displaces the chloride atom via an addition elimination reaction as 
shown in Figure 18.  Delocalization of negative charge over the 1- and 3- position electronega-
tive N atoms supports the displacement of the 2-position chlorine atom by the nitrogen nucleo-
phile.  The anionic intermediates are stabilized by both nitrogen atoms as shown in the mesomer-
ic isomers which promote substitution of the halogen atom .   
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Figure 18. Proposed mechanism for the addition elimination of the chlorine atom by N-
methylpiperazine. 
 
The NMR spectra of  compounds 9 -12 retain the signal pattern of their corresponding 2-
chloro intermediate compounds 2 - 5, slightly shifted; however, they now also feature the charac-
teristic methylpiperazine peaks; a singlet signal representing the three methyl hydrogens and two 
triplet peaks corresponding to the hydrogens of the four methylene group  of the piperazine ring. 
2.2 Synthesis of Substituted Pyridines 
 Several compounds demonstrating selective affinity to the 5-HT7 receptor feature a pyri-
dine moiety.  Foregoing research has expanded the class of 5-HT7 receptor ligands to include 
novel thiopyridines, aminopyridines, and arylpyridines as have been described..
15, 22,27
  The syn-
thesis of disubstituted pyridine compounds presented in this thesis has been achieved with me-
thods incorporating organometallic catalysis.    
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2.2.1 Suzuki Coupling to Bromopyridine via Palladium Catalysis 
In 1981, the continued research of Suzuki and Miyaura efforts afforded an efficient me-
thodology for the synthesis of biaryl compounds through the palladium catalyzed cross-coupling 
of aryl boronic acids with aryl halides.
56
  In what has become known as the Suzuki cross-
coupling reaction, palladium facilitates the carbon-carbon coupling between organoboron com-
pounds and organic halides or triflates.
56
 This method of coupling is both stereo- and regioselec-
tive and provides an efficient means for the synthesis of biaryl compounds.   
Addition to 4-bromo-2-chloropyridine was achieved via Suzuki coupling.  The reaction 
of the nitrogen heterocycle with a heteroarylboronic acid in the presence of strong base yielded 
the substituted products 15-18 as shown in Scheme 4.  Attack at the 4-bromo position was fa-
vored over that at the 2-chloro position.  This occurrence is attributed to the larger size and de-
creased basicity of the bromine atom.    
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Scheme 4. 
 
NMR spectroscopic analysis of compound 15 featured several peaks within the aromatic region.  
A doublet at 8.40 ppm with a coupling constant of 5.2 Hz corresponded to the 3-position H atom 
of the pyridine ring.  The multiplet peak signals apparent at 7.40 and 7.45 ppm represent the  
protons of  the 5- and 6-postions of the pyridine ring overlapped with protons of the .  These hy-
drogen atoms experience significant coupling and thus exhibit multiple signals. 
1
HNMR spectra 
of compounds 16  and  17  bear similar peak signal patterns thus confirming addition of the hete-
roaryl group.      
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The reaction of the 4-bromo-2-chloropyridine with the Pd(0)
 
species formed a Pd(II)-
halide-aryl complex in the oxidative addition step as shown in Figure 19.
57
  In the ancillary meta-
thesis stage, the bromide anion of the Pd(II) complex is exchanged for the basic anion.  During 
transmetallation, the in situ generated tetravalent borate complex readily exchanges the aryl 
group for the anion of the Pd(II)-aryl-anion complex.  The bis-aryl Pd(II) complex undergoes 
reductive elimination and the Pd(0)
 
catalyst
 
is regenerated with the formation of a new carbon-
carbon bond between the pyridine ring and the heteroaryl affording compounds 15 - 17.  
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Figure 19. The mechanism of the Suzuki cross-coupling reaction of 4bromo-2-chloropyridine 
and an arylboronic acid.
56
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Heating of compounds 15 – 17 in neat methylpiperazine afforded compounds  18 – 21  in 
appreciable yields.  Resonance analysis of these compounds feature the respective heteroaryl and 
pyridine peaks of compounds 15 – 17.  Peak signals corresponding  methyl piperazine peaks, 
however, are also apparent in these spectra confirming displacement of the 2-position chlorine 
atom  by the nitrogen nucleophile N-methylpiperazine. 
2.2.2 Amination of Di-bromopyridine via Palladium Catalysis 
Established methods for the formation of a C – N bond typically feature harsh reaction 
conditions, difficult copper reagents, toxic organostannanes, non-regiospecificity in product, or 
low synthetic yield.
57,58
  In 1995, Buchwald and Hartwig independently reported the transition 
metal catalyzed hetero cross-coupling between aryl halides and amines under basic conditions.
59
  
The Buchwald-Hartwig reaction has provided an efficient means for the addition of N-
methylpiperazine to position 2 of 2,6-dibromopyridine as shown in Scheme 5. 
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Scheme 5. 
 
A proposed mechanism for the catalytic cycle of the amination of 2,6-dibromopyridine is 
presented in Figure 20.  The reaction of BINAP with the palladium catalyst Pd2(dba)3 forms a 
complex which undergoes oxidative addition to form a BINAP –Pd-halopyridine complex.  This 
complex can coordinate directly to the N-methylpiperazine prior a deprotonation 
/transmetallation step in which the halide is transferred to the metal cation of the base sodium 
tert-butoxide providing the BINAP-Pd(II)-aryl-amino complex.  Alternatively, metathesis may 
succeed oxidative addition and the halide is exchanged for the basic anion generating the BI-
NAP-Pd(II)-aryl-anion complex.  The methylpiperazine is coordinated in the transmetallation 
step affording the BINAP-Pd(II)-aryl-amino complex.   The resulting complex undergoes reduc-
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tive elimination regenerating the original BINAP-Pd(0) complex and affording the desired aryl-
amino compound 22.
59
 
 
1. oxidative Additon3. reductive 
    elimination
(BINAP)Pd(0)
BINAP-Pd(II)
NN CH3H
HOtBu
2. transmetallation
Ar
N
N
H3C
(or deprotonation step)
Ar Br
Ar
Na OtBu
NaBr
OtBu
BINAP-Pd(II)
Ar
Br
BINAP-Pd(II)
Ar
N
N
H
CH3
NN CH3H
N
BINAP-Pd(II)
Ar
N
CH3
Na OtBu
HOtBu
NaBr
(metathesis)
Br
 
Figure 20. A proposed mechanism for the Buchwald-Hartwig amination of 2,6-dibromopyridine. 
 
 
The palladium catalyst in the presence of strong base BINAP facilitated the addition of 1-
methylpiperazine to 2,6-dibromopyridine for 22 as shown in Scheme 5.  It is prosposed that BI-
NAP prevented the generation of the catalytically inert bis-amino-Pd(II).
59
 
Proton NMR spectroscopic analysis of 23 featured distinctive pyridine peak signals at 
6.36, 6.56, and 7.11 ppm.  The characteristic peaks corresponding to N-methylpiperazine are also 
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apparent.  The singlet at 2.16 ppm corresponds to the three protons of the methyl group.  Coupl-
ing  exhibited among the hydrogens of the methylene groups of the pyridine ring is demonstrated 
by the two triplet peak signals at 2.30 and 3.37 ppm.   
Compounds 23 – 25 were then prepared under the conditions outlined for Suzuki coupl-
ing above using 22 as the halopyridine reagent.  These compounds retained  the pattern of the 
NMR signals of the starting compound 22.  The NMR spectra now also features the signals in-
dicative of their respective heteroaryl moieties, peak signals within the aromatic region 6.0 – 8.0 
ppm. 
  
2.3 Biological activity of Substituted Pyrimidines and Pyridines 
Biological affinities to the 5-HT7 receptor for selected purified pyrimidines and pyridines 
were obtained.  Several of the synthesized disubstituted pyrimidines were too hygroscopic tof 
form hydrobromic acid salts for biological testing. Salts for pyrimidine (12) and pyridine (18 – 
21 and 23 -25) compounds were shipped to collaborative researchers at  the  Institute of  Phar-
macology of the Polish Academy of Sciences.  Values were also determined for binding to the 5-
HT2 and 5-HT6 receptors as they are structurally and physiologically comparable.  Results are 
presented in Table 1.1 
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Table 1.1 Biological Activities 
Compound 
Ki 
5-HT2A (nM) 
Ki 
5-HT7 (nM) 
Ki 
5-HT6 (nM) 
N
NN
N
H3C
N
N
 
561 757 24820 
N
N
N
S
CH3
 
89 79 203 
N
N
N
O
CH3
 
41 17 417 
N
N
N
S
CH3  
150 396 785 
N
O
N
N
CH3
 
163 11 982 
N
N
N
O
CH3  
328 307 2803 
N
O
N
N
CH3
 
1936 1135 3405 
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Compound s 19 and 24 demonstrate the highest affinity and selectivity to the 5-HT7 receptor over 
5-HT2 and 5-HT6 receptors.  It is proposed that the position of the heteroaryl substituent, the he-
teroatom, and the position of the heteroatom in the ring have affected the efficacy of binding.  
The 3-furyl moiety of the 2,4-disubstituted (19, Ki = 17 nM, pKi = 7.77) and the 2,6- disubsti-
tuted (24, Ki = 11 nM, pKi = 7.96) pyridines demonstrate highest affinity among the compounds 
tested.  It is likely that the heteroaryl moiety of these substituted pyridines would correspond to 
the hydrophobic (HYD) or aromatic (AR) group as proposed in several of the pharmacophoric 
models, in particular, that presented by Bojarski.  The identity of the heteroatom (i.e., oxygen vs. 
sulfur) and the position (i.e., 2- vs. 3-) can affect interaction at the binding site.  The 3-furyl 
group of 19 and 24 HYD/AR may engage in the strongest interaction with the aromatic phenyl 
groups of the phenylalanine and tyrosine of the binding site.
38,39
  
3 EXPERIMENTAL 
3.1 Synthesis of 2,4-Disubstituted Pyrimidines 
4-vinyl-2chloropyrimidine (1).  A solution of tetravinyl tin (1.29 ml, 7.1 mmol) in THF (2 ml) 
was stirred under nitrogen atmosphere.  The temperature of the solution was lowered to     -78 °C 
and 3.54 ml (6.0 mmol) of tert-butyllithium was added.    After 10 min, white precipitate had 
formed and 0.75 g (5.3 mmol) of 2-chloropyrimidine was added dropwise.  The temperature was 
allowed to reach -30 °C and the vessel removed from the nitrogen atmosphere.  The temperature 
was decreased to -78 °C. To quench the reaction, a mixture of deionized water (5 ml) and THF (5 
ml) was added.  Following the water mixture, one molar equivalent of 2,3-dichloro-5,6-dicyano-
1,4-benzoquinone DDQ (1.23 g) dissolved in THF was added.  Aqueous NaOH (0.3 g) was then 
added until the mixture became basic.  The mixture was extracted with   20 ml hexanes:THF (2 x 
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20 ml, 1:1).  The extract was dried with magnesium sulfate, filtered, and then concentrated under 
reduced pressure.  The residual oil was purified by chromatograph on silica gel using a mobile 
phase of hexanes: dichloromethane (3:1); yield 0.390 g (2.78 mmol, 52 %) of 1. 
1
HNMR (400 
MHz, CDCl3): δ 5.79 (dd, J = 12.6 Hz, 0.8 Hz, 1H, -CH), 6.51 (dd, J = 17.2 Hz, 0.8 Hz, 1H, -
CH), 6.68 (dd, J = 17.2 Hz, 10.4 Hz, 1H, -CH), 7.2 (d, J = 5.2 Hz, 1H, -CH), 8.84 (d, J = 5.2 Hz, 
1H, -CH). 
13
CNMR (CDCl3): δ 165.5, 161.6, 159.9, 133.9, 125.3, 116.5. High-resolution MS 
(ESI, positive ion mode): calcd. for C6H5ClN2 (M + 1)
+
, m/z 141.0218; found m/z 141.0220.
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2-(2-Chloropyrimidin-4-yl)-N-ethylethanamine (2). Ethylamine (0.08 ml, 0.99 mmol) was 
added to a solution of 1 (0.20 g, 1.00  mmol) in 2 ml of toluene.  The mixture was stirred for 48 
h, monitored with TLC at 24 h intervals.  Deionized water (2 ml) was added to quench the reac-
tion.  Aqueous Na2CO3 (0.30 g in 1 ml water) was then added.  The resulting solution was ex-
tracted with hexanes: THF (2 x 20 ml, 1:1) and dried over magnesium sulfate.  The pale yellow 
oil was purified by chromatography on silica gel eluting with hexanes and then hexanes/ ethyl 
acetate (4 : 3) followed by 1:1 dichloromethane/methanol) to yield 0.055 g (0.30 mmol, 30%) of 
2. 
1
HNMR (400 MHz, CDCl3): δ 1.10 (t, J = 3.2 Hz, 3H, -CH3), 1.91 (s, 1H, -NH), 2.69 (q, J = 
3.2 Hz, 2H, -CH2-), 2.95 (t, J = 6.8 Hz, 2H, -CH2-), 3.04 (t, J = 6.8 Hz, 2H, -CH2-), 7.17 (d, J = 
5.2 Hz, 1H, -CH), 8.49 (d, J = 5.2 Hz, 1H, -CH). 
13
CNMR (400 MHz, CDCl3): δ 172.6, 161.3, 
159.1, 119.3, 47.7, 43.9, 37.8, 151.  High resolution ms (ESI, positive ion mode): calcd. for 
C8H13N3Cl (M + 1)
+
, m/z 186.0798; found m/z 186.0798. 
 
General Procedure for 3,4 
Nucleophiles (1.40 mmol) were added to 1 (1.40 mmol) stirring in 1 ml toluene.  The mixture 
was then stirred overnight at room temperature.  A TLC analysis indicated the absence of 1.  Wa-
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ter (5 ml) was added and the solution was extracted with ether (2 x 20 ml).  The organic layers 
were collected, dried over magnesium sulfate, and concentrated under reduced pressure. 
N-(2-(2-Chloropyrimidin-4-yl)ethyl)-2-methylpropan-2-amine (3). 
The pale yellow oil was purified by chromatography on silica gel eluting with dichloromethane 
to yield 0.082 g of 3 (0.38 mmol, 38%). 
1
HNMR (400 MHz, CDCl3): δ 1.09 (s, 9H, -C(CH3)3), 
2.91 (t, J = 6.0 Hz, 2H, -CH2-), 2.97 (t, J = 6.0 Hz, 2H, -CH2-), 7.21 (d, J = 4.8 Hz, 1H, -CH), 
8.50 (d, J = 4.8 Hz, 1H, -CH). 
13
CNMR (400 MHz, CDCl3) : δ 173.0, 161.3, 159.0, 119.4, 50.5, 
41.1, 39.0, 29.0.  High resolution ms (ESI, negative ion mode): calcd. for C10H15N3Cl (M - H)
-
, 
m/z 212.0955; found m/z 212.0947. 
N-(2-(2-Chloropyrimidin-4-yl)ethyl)butan-1-amine (4).  The yellow oil was purified by chro-
matography dichloromethane followed by dichloromethane/ ethyl acetate/ methanol (4: 3: 1) to 
yield 4 (0.14 g, 0.64 mmol, 46 %). 
1
HNMR (400 MHz, CDCl3): δ 0.91 (t, J = 7.2 Hz, 3H, -CH3), 
1.33 (m, 2H, -CH2-), 1.46 (m, H, -CH2), 2.64 (t, J = 7.2 Hz, 2H, -CH2-), 2.95 (t, J = 6.4 Hz, 2H, -
CH2-), 3.03 (t, J = 6.4 Hz, 2H, -CH2-), 7.17 (d, J = 5 Hz, 1H, -CH), 8.50 (d, J = 5 Hz, 1H, -CH).  
High resolution ms (ESI, negative ion mode): calcd. for C10H15N3Cl (M - H)
-
, m/z 212.0955; 
found m/z 212.0933. 
2-Chloro-4-(2-(4-phenylpiperazino)ethyl)pyrimidine (5).  N-Phenylpiperazine (0.275 g, 1.96 
mmol) was added to a solution of 1 (0.3 ml, 1.96 mmol) in 2 ml toluene.  The mixture was 
heated under reflux for refluxed 2 h.  The mixture was then quenched with a solution of sodium 
carbonate in 5 ml water.  The mixture was allowed to reach room temperatrue before extraction 
with ether (2 x 20 ml).  The organic layers were collected, dried over magnesium sulfate, filtered 
and concentrated under reduced pressure.  The residual yellow oil was purified by chromatogra-
phy eluting with hexanes/ethyl acetate  (4: 1) then hexanes/ ethyl acetate/ ethanol  (8: 6: 1) to 
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yield 0.13 g of 6 (0.43 mmol, 22 %).  
1
HNMR (400 MHz, CDCl3): δ 2.68 (t, J = 4.8 Hz, 4H, -
CH2-), 2.83 (t, J = 6.6 Hz, 2H, -CH2-), 2.98 (t, J = 6.6 Hz, 2H, -CH2-), 3.20 (t, J = 4.8 Hz, 4H, -
CH2), 6.85 (m, 1H, -CH), 6.93 (m, 2H, -CH), 7.20 (d, J = 6 Hz, 1H, -CH), 7.26 (m, 2H, -CH), 
8.49 (d, J = 6 Hz, 1H, -CH).  
13
CNMR (400 MHz, CDCl3): δ 172.8, 161.2, 159.1, 151.2, 129.1, 
119.8, 119.3, 116.1, 56.7, 53.0, 49.1, 35.1.   
N,N-Bis-[2-(2-chloro-pyrimidin-4-yl)ethylamine (6).  Ethylamine (0.08 ml, 0.99 mmol) was 
added to a solution of 1 (0.25 g, 1.79  mmol) in 2 ml of toluene.  The mixture was stirred for 48 
h, monitored with TLC at 24 h intervals.  Deionized water (2 ml) was added to quench the reac-
tion.  Aqueous Na2CO3 (0.30 g in 1 ml water) was then added.  The resulting solution was ex-
tracted with hexanes: THF (2 x 20 ml, 1:1) and dried over magnesium sulfate.  The solution was 
concentrated under reduced pressure and purified by chromatography on silica gel eluting with 
hexanes:/iethyl ether/methanol (4:1:1) to yield 0.085 g (0.26 mmol, 26%) of 12. 
1
HNMR (400 
MHz, CDCl3): δ 1.0 (t, J = 7.2 Hz, 3H, -CH3), 1.62 (br s, 1H, -NH), 2.58 (q,   J = 7.2 Hz, 2H, -
CH2-), 2.88 (dt, J = 23.6 Hz, 6.0 Hz, 2H, -CH2-), 7.03 (d, J = 5.2 Hz, 1H, -CH), 8.44 (d, J = 5.2 
Hz, 1H, -CH).  
13
CNMR (400 MHz, CDCl3): δ 173.1, 161.2, 158.9, 119.4, 51.9, 47.0, 35.4, 11.7. 
High resolution ms (ESI, positive ion mode): calcd. for C21H31N6 (M + 1)
+
, m/z   367.2610; 
found m/z 367.2609. 
2-Chloro-4-(2-(phenylthio)ethyl)pyrimidine (7).   Sodium benzenethiolate (0.135 g, 1.00 
mmol) was added to 1 (0.140 g, 1.00 mmol) stirring in 1 ml of toluene.  The mixture was ref-
luxed 6 hrs before quenching with 5 ml water.  Ether was added and the mixture partitioned be-
tween ether and water (2 x 10 ml).  The organic layers were collected, dried over magnesium sul-
fate, and concentrated under reduced pressure.  The residual yellow oil was purified with  hex-
anes/dichloromethane (100 : 0 and then 9:1) to yield 0.090 g of 9 (0.02 mmol, 3 %).  
1
HNMR 
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(400 MHz, CDCl3): δ 3.08 (t, J = 7 Hz, 2H, -CH2-), 3.36 (t, J = 7 Hz, 2H, -CH2-), 7.12 (d, J = 5 
Hz, 1H, -CH), 7.32 (m, 5H, -Ar), 8.51 (d, J = 5 Hz, 1H, -CH).  
13
CNMR (400 MHz, CDCl3): δ 
171.8, 159.2, 135.1, 130.1, 129.1, 126.7, 119.4, 37.1, 32.1.   
2-(Phenylthio)-4-(2-(phenylthio)ethyl)pyrimidine (8).  A solution of sodium benzenethiolate 
(0.135 g, 1.00 mmol, in 1 ml anhydrous tetrahydrofuran) was added to 1 stirring in 1 ml of tolu-
ene.  The mixture was heated under reflux for 6 h before quenching with 5 ml water and ex-
tracted with ether/water (2 x 40 ml).  The organic layers were collected, dried over magnesium 
sulfate, and concentrated under reduced pressure.  The residual yellow oil was purified by chro-
matography eluting with hexanes/dichloromethane (100 : 0) to yield 0.03 g 11 (0.09 mmol, 9 %).  
1
HNMR (400 MHz, CDCl3): δ 2.95 (t, J = 7.4 Hz, 2H, -CH2-), 3.23 (t, J = 7.4 Hz, 2H, -CH2), 
6.35 (d, J = 5 Hz, 1H, -CH), 7.19 (m, 1H, -CH), 7.29 (m, 1H, -CH), 7.37 (m, 1H, -CH), 8.18 (d, J 
= 5 Hz, 1H, -CH).  
13
CNMR (400 MHz, CDCl3): δ 172.4, 168.6, 157.4, 135.5, 135.3, 129.7, 
129.5, 129.1, 129.1, 129.0, 126.3, 116.6, 38.8, 36.8. High resolution ms (ESI, positive ion 
mode): calcd. for C17H18S2N2 (M + 1)
+
, m/z   325.0833; found m/z 325.0829. 
General procedure for 9 - 14 
Neat N-methylpiperazine (1.30 mmol) was added to the 2-chloro-4-vinylpyrimidine compound 2 
– 5 (0.65 mmol) stirring in 1 ml toluene.  The mixture was heated under reflux for 3 h after 
which time a TLC analysis indicated the absence of the starting material, compounds 2 - 5.  The 
mixture  was then quenched with water (5 ml).  The mixture was allowed to reach room tempera-
ture before extraction with ether (2 x 20 ml).  The organic phases were collected, dried over 
magnesium sulfate, filtered, and concentrated under reduced pressure to afford a yellow oil. 
N-ethyl-2-(2-(4-methylpiperazin-1-yl)pyrimidin-4-yl)ethanamine (9).  This compound was 
obtained according to the general procedure above.  The yellow oil obtained was purified with 
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dichloromethane/methanol (100: 0, then 1:1) to yield 0.021 g of 7 (0.08 mmol, 30 %).  
1
HNMR 
(400 MHz, CDCl3): δ 1.11 (t, J = 7.2 Hz, 3H, -CH3), 2.34 (s, 3H, -CH3), 2.46 (t, J = 5 Hz, 2 H, -
CH2-), 2.68 (q, J = 6.8 Hz, 2H, -CH2-), 2.79 (t, J = 6.6 Hz, 2H, -CH2-), 2.98 (t, J = 6.6 Hz, 2H, -
CH2-), 3.87 (t, J = 5 Hz, 2H, -CH2-), 6.38 (d, J = 4.8 Hz, 1H, -CH), 8.19 (d, J = 4.8 Hz, 1H, -
CH).  
13
CNMR (400 MHz, CDCl3): δ 166.8, 161.0, 158.8, 111.2, 52.6, 44.5, 42.8, 42.63, 41.0, 
33.2. High resolution ms (ESI, positive ion mode): calcd. for C13H24N5 (M + 1)
+
, m/z   250.2032; 
found m/z 250.2024. 
Synthesis of 2-methyl-N-(2-(2-(4-methylpiperazin-1-yl)pyrimidin-4-yl)ethyl)propan-2-
amine (10).  This compound was obtained according to the general procedure above.  The yel-
low oil was purified with a mobile phase of dichloromethane: ethyl acetate: methanol (8: 6: 3) to 
yield 0.05 g 8 (0.17 mmol, 31 %).    
1
HNMR (400 MHz, CDCl3): δ 1.11 (s, 9H, -C(CH3)3), 2.35 
(s, 3H, -CH3), 2.48 (t, J = 4.8 Hz, 3H, -CH2-), 2.77 (t, J = 6.8 Hz, 2H, -CH2-), 2.96 (t, J = 6.8 Hz, 
2H, -CH2-), 3.86 (t, J = 4.8 Hz, 2H, -CH2-), 6.41 (d, J = 5 Hz, 2H, -CH2-), 8.20 (d, J = 5 Hz, 2H, 
-CH2-).  
13
CNMR (400 MHz, CDCl3): δ 169.5, 161.7, 157.4, 109.4, 55.0, 50.3, 46.3, 43.7, 40.9, 
34.9, 38.5, 29.0. High resolution ms (ESI, positive ion mode): calcd. for C15H28N5 (M + 1)
+
, m/z   
278.2345; found m/z 278.2345. 
 
N-(2-(2-(4-Methylpiperazino)pyrimidin-4-yl)ethyl)butan-1-amine (11).  The yellow oil was 
purified by chromatography with an eluent of dichloromethane/ethyl acetate/methanol (4: 3: 1) to 
yield 0.054 g of 7 (0.19 mmol, 30%).  
1
HNMR (400 MHz, CDCl3): δ 0.92 (t, J = 7.2 Hz, 3H, -
CH3), 1.34 (m, 2H, -CH2-), 1.46 (m, 2H, -CH2-), 1.82 (br s, 1H, -NH), 2.34 (s, 3H, -CH3), 2.47 (t, 
J = 5 Hz, 4H, -CH2-), 2.63 (t, J = 7.2 Hz, 2H, -CH2-), 2.77 (t, J = 6.6 Hz, 2H, -CH2-), 2.98 (t, J = 
6.6 Hz, 2H, -CH2-), 3.84 (t, J = 5 Hz, 4H, -CH2-), 6.39 (d, J = 5 Hz, 1H, -CH), 8.19 (d, J = 5 Hz, 
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1H, -CH).  
13
CNMR (400 MHz, CDCl3): δ 169.4, 161.7, 157.4, 109.3, 55.0, 52.6, 49.5, 48.2, 
46.3, 43.6, 37.7, 35.4, 32.3, 20.6, 14.0.  High resolution ms (ESI, positive ion mode): calcd. for 
C15H28N5 (M + 1)
+
, m/z   278.2345; found m/z 278.2340. 
2-(4-Methylpiperazin-1-yl)-4-(2-(4-phenylpiperazino)ethylpyrimidine (12).  The yellow oil 
was purified by chromatography eluting with dichloromethane/ethyl acetate/methanol (4: 3: 1) to 
yield 0.065 g 8 (0.18 mmol, 35 %).  
1
HNMR (400 MHz, CDCl3):  δ 2.34 (t, I = 6 Hz, 3H, -CH2-), 
2.48 (t, J = 4.8 Hz, 4H, -CH2-), 2.70 (t, J = 4.8 Hz, 4H, -CH2-), 2.81(m, 4H, -CH2-), 3.23 (t, J = 
4.8 Hz, 4H, -CH2-), 3.85 (t, J = 4.8 Hz, 4H, -CH2-), 6.42 (d, J = 4.8 Hz, 1H, -CH), 6.86 (m, 1H, -
CH), 6.95 (m, 1H, -CH), 7.27 (m, 1H, -CH), 8.20 (d, J = 4.8 Hz, 1H, -CH). High resolution ms 
(ESI, positive ion mode): calcd. for C21H31N6 (M + 1)
+
, m/z   367.2610; found m/z 367.2609. A 
hydrobromide salt was prepared according to general procedure above. Anal. calcd. For 
C21H34N6•3HBr,0.5H2O: C, 40.80; H, 5.54; N, 13.59; found C, 40.65; H, 5.96; N, 13.56. 
N,N-Bis-[2-(2-(4-methylpiperazin-1-yl)pyrimidin-4-yl)ethylamine (13).  
N-Methylpiperazine (0.12 ml, 1.11 mmol) was added to a solution of 2 (0.12 g, 0.37 mmol) in 1 
ml toluene.  The mixture was refluxed for 1 h and monitored with TLC analysis until the absence 
of 2 was apparent.  Water (5 ml) was added and the mixture extracted with hexanes/diethyl ether 
(2 x 20 ml, 1:1).  The organic layers were collected, dried over magnesium sulfate, and concen-
trated under reduced pressure.  The pale yellow oil was purified by chromatography on silica gel 
with a mobile phase of dichloromethane/methanol (1:1) to yield 0.045 g of 13 (0.10 mmol, 28%). 
1
HNMR (400 MHz, CDCl3): δ 1.07 (t, J = 7.2 Hz, 3H, -CH3), 2.35 (s, 3H, -CH3), 2.48 (t, J = 5.0 
Hz, 2H, -CH2-), 2.73 (m, 4H, -CH2-), 2.91 (m, 4H, -CH2-), 3.86 (t, J = 5.0 Hz, 2H, -CH2-), 6.37 
(d, J = 4.8 Hz, 2H, -CH), 8.18 (d, J = 4.8 Hz, 2H, -CH).  
13
CNMR (400 MHz, CDCl3): δ 169.8, 
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162.0, 157.2, 109.4, 55.0, 52.0, 47.4, 46.3, 43.7, 35.4, 12.2. High resolution ms (ESI, positive ion 
mode): calcd. for C24H40N9 (M + 1)
+
, m/z   454.3407; found m/z 454.3405. 
2-(4-Methylpiperazino)-4-(2-(phenylthio)ethyl)pyrimidine (14).  The yellow oil was purified 
by chromatography eluent with dichloromethane/methanol (100: 0, then 20: 1) to yield 0.014 g 
10 (0.04 mmol, 63 %).  
1
HNMR (400 MHz, CDCl3):  2.35 (s, 3H, -CH3), 2.47 (t, J = 5 Hz, 4H, -
CH2-), 2.88 (t, J = 7 Hz, 2H, -CH2-), 3.31 (t, J = 7 Hz, 2H, -CH2-), 3.85 (t, J = 5 Hz, 4H, -CH2-), 
6.35 (d, J = 4.8 Hz, 2H, -CH2-), 7.19 (m, 1H, -CH), 7.27 (m, 2H, -CH), 7.37 (d, J = 3.8 Hz, 2H, -
CH), 8.18 (d, J = 4.8 Hz, 1H, -CH).  
13
CNMR (400 MHz, CDCl3): 177.7, 168.5, 157.6, 129.4, 
128.9, 128.9, 126.1, 109.2, 55.0, 46.2, 43.6, 37.3, 31.8. High resolution ms (ESI, positive ion 
mode): calcd. for C17H23N4S (M + 1)
+
, m/z   315.1643; found m/z 315.1648. 
 
3.2 Synthesis of Disubstituted Pyridines 
All reaction  employed a palladium bidentate catalyst.  The catalyst aided in substitution of the 
pyridine compounds.   
3.2.1 Preparation of 2,4-Disubstituted Pyridines 
2-Chloro-4-(3-thienyl)pyridine (15).  A solution of 4-bromo-2-chloro-pyridine (0.15 ml, 1.35 
mmol) and thiophene-3-boronic acid (0.09 g, 0.683 mmol) in 5 ml of 1,4 dioxane under nitrogen 
atomospere was treated with [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) 
(Pd(dppf)2Cl2, 0.02 g, 0.02 mmol) and potassium phosphate dibasic (0.28 g, 1.64 mmol).  The 
mixture was heated under reflux for 48 h.  The vessel was removed from the heat source and its 
temperature allowed to reach room temperature.  The mixture was vacuum filtered through 0.5 
cm of Celite ® and washed with ether (10 ml).  The filtrate was concentrated under reduced 
pressure.
8
  Purification of the yellow-brown oil was achieved by chromatography with an eluent 
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of hexanes on silica gel to yield 0.034 g of 15 (0.27 mmol, 20 %).  
1
HNMR (400 MHz, CDCl3): 
δ 7.40 (m, 2H, -CH), 7.45 (m, 1H, -CH), 7.52 (s, 1H, -CH), 7.70 (m, 1H, -CH), 8.40 (d, J = 5.2 
Hz, 1H, -CH).  
13
CNMR (400 MHz, CDCl3): δ 152.4, 150.1, 145.7, 138.2, 127.5, 125.6, 124.1, 
121.1, 119.7. High resolution ms (ESI, positive ion mode): calcd. for C9H6ClNS (M + 1)
+
, m/z 
195.9988; found m/z 195.9979. 
2-Chloro-4-(3-furyl)pyridine (16).  Furan-3-boronic acid (0.38 g, 3.38 mmol), Pd(dppf)2Cl2 
(0.09 g, 0.11 mmol), and potassium phosphate dibasic (1.18 g, 6.75 mmol) were added to a solu-
tion of 4-bromo-2-chloro-pyridine (0.25 ml, 2.25 mmol) in 5 ml dioxane under a nitrogen ato-
mosphere.  The mixture was heated under reflux for 72 h before removal from the heat source 
and the temperature allowed to reach room temperature.  The mixture was filtered through 0.5 
cm Celite ® and washed with ether (10 ml).  The filtrate was concentrated under reduced pres-
sure.
9
 The yellow oil obtained was purified by chromatography with hexanes to yield 0.099 g of 
16 (0.54 mmol, 24 %).  
1
HNMR (400 MHz, CDCl3): δ 6.69 (d, J = 0.6 Hz, 1H, -CH), 7.25 (d, J = 
2.6 Hz, 1H, -CH), 7.34 (s, 1H, -CH), 7.50 (d, J = 0.6 Hz, 1H, -CH), 7.86 (s, 1H, -CH), 8.31 (d, J 
= 2.6 Hz).  
13
CNMR (400 MHz, CDCl3): δ 152.3, 150.1, 114.7, 143.4, 140.9, 123.3, 120.6, 
119.1, 108.2.  High resolution ms (ESI, positive ion mode): calcd. for C9H6ClNO (M + 1)
+
, m/z 
180.0216; found m/z 180.0224. 
2-Chloro-4-(2-thienyl)pyridine (17).  Thiophene-2-boronoic acid (0.43 g, 3.38 mmol), tetra-
kis(triphenylphosphine) palladium Pd(PPh3)4 (0.20 g, 0.18 mmol), and potassium carbonate (0.93 
g, 6.75 mmol) were added to 4-bromo-2-chloropyridine (0.25 ml, 2.25 mmol) stirring in 6 ml 
dioxane under a nitrogen atomosphere.  The mixture was heated to reflux for 96 h.  After remov-
al of the reaction vessel from the heat source, the temperature was allowed to reach room tem-
perature before filtration through 0.5 cm Celite ®.  The filtrate was concentrated under reduced 
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pressure.
9
  The yellow oil was purified with hexanes to yield 0.214 g of 17 (1.09 mmol, 49 %).  
1
HNMR (400 MHz, CDCl3): δ 7.08 (m, 1H, -CH), 7.32 (m, 1H, -CH), 7.41 (m, 1H, -CH), 7.44 
(m, 2H, -CH), 8.29 (d, J = 2.6 Hz, 1H, -CH).  
13
CNMR (400 MHz, CDCl3): 152.4, 150.1, 144.4, 
140.0, 128.6, 128.1, 126.2, 120.1, 118.8.  High resolution ms (ESI, positive ion mode): calcd. for 
C9H7NSCl (M + 1)
+
, m/z 195.9988; found m/z 195.9989.   
1-Methyl-4-(4-(3-thienyl)pyridin-2-yl)piperazine (18).  A stirring mixture of 1-
methylpiperazine (1 ml) and 15 (0.08 g, 0.38 mmol) was heated to 200 °C overnight in a sealed 
tube.  The reaction mixture was cooled to room temperature and concentrated under reduced 
pressure.  The resulting brown oil was purified with a mobile phase of dichloromethane: metha-
nol (8 : 1) to yield 0.079 g 18 (0.31 mmol, 80 %).  
1
HNMR (400 MHz, CDCl3): δ 2.34 (s, 3H, -
CH3), 2.53 (t, J = 5.0 Hz, 2H, -CH2-), 3.61 (t, J = 5.0 Hz, 2H, -CH2-), 6.82 (m, 2H, -CH), 7.29 
(m, 2H, -CH), 7.56 (s, 1H, -CH), 8.19 (m, 1H, -CH).  
13
CNMR (400 MHz, CDCl3): δ 160.2, 
148.5, 144.3, 140.7, 126.6, 126.0, 122.4, 111.5, 104.1, 54.9, 46.2, 45.3.  High resolution ms (ESI, 
positive ion mode): calcd. for C14H17N3S (M + 1)
+
, m/z 260.1221 found m/z 260.1223. 
1-(4-(3-Furyl)pyridine-2-yl)-4-methylpiperazine (19).  A stirring mixture of 1-
methylpiperazine (1 ml) and 16 (0.08 g, 0.43 mmol) was heated to 200 °C overnight in a sealed 
tube.  The mixture was removed from the heat source and allowed to reach room temperature.  
Ether (20 ml) was added and the solution concentrated under reduced pressure.  The brown oil 
was purified with by chromatography eluting with dichloromethane/methanol (95 : 5) to yield 
0.075 g of 19 (0.30 mmol, 71 %).  
1
HNMR (400 MHz, CDCl3): δ 2.34 (s, 3H, -CH3), 2.53 (t, J = 
5.0 Hz, 2H, -CH2-), 3.60 (t, J = 5.0 Hz, 2H, -CH2-), 6.72 (m, 3H, -CH), 7.49 (m, 1H, -CH), 7.81 
(s, 1H, -CH), 8.16 (m, 1H, -CH).  
13
CNMR (400 MHz, CDCl3): δ 160.1, 148.35, 144.0, 141.4, 
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140.0, 125.2, 110.9, 108.5, 103.5, 54.87, 46.1, 45.2.  Anal. calcd. For C14H17N3O•2HBr: C, 
41.51; H, 4.73; N, 10.37; found C, 41.04; H, 4.39; N, 11.07. 
1-Methyl-4-(4-(2-thienyl)pyridin-2-yl)piperazine (20). A mixture of 1-methylpiperazine (1 ml) 
and 17 (0.11 g, 0.56 mmol) was stirred overnight at 200 °C in a sealed tube.  The mixture was 
removed from the heat source and allowed to reach room temperature.  Ether (20 ml) was added 
and the solution concentrated under reduced pressure.  The residual brown oil was purified by 
chromatography eluting with hexanes: dichloromethane (9: 1) to yield 0.064 g of 20 (0.25 mmol, 
45 %).  
1
HNMR (400 MHz, CDCl3): δ 2.36 (s, 3H, -CH3), 2.55 (t, J = 5.0 Hz, 2H, -CH2-), 3.62 
(t, J = 5.0 Hz, 2H, -CH2-), 6.83 (s, 1H, -CH), 6.86 (d, J = 5.2 Hz, 1H, -CH), 7.11 (dd, J = 4.0 Hz, 
J = 4.8 Hz, 1H, -CH), 7.36 (d, J = 4.4 Hz, 1H, -CH), 7.44 (d, J = 2.8 Hz, 1H, -CH), 8.18 (d, J = 
5.2 Hz, 1H, -CH).  
13
CNMR (400 MHz, CDCl3): δ 160.1148.5, 142.8, 142.5, 128.1, 126.3, 124.8, 
110.7, 103.2, 54.9, 46.2, 45.3.  A hydrobromide salt was prepared according to general procedure 
above. Anal. calcd. For C14H17N3S•2HBr,0.5H2O: C, 39.09; H, 4.69; N, 9.77; found C, 39.46; H, 
4.80; N, 9.34. 
1-(4-(2-Furyl)pyridin-2-yl)-4-methylpiperazine (21).  (a) Furan-2-boronic acid (0.30 g, 2.7 
mmol), Pd(PPh3)4 (0.15 g, 0.18 mmol), and potassium carbonatec (0.933 g, 6.75 mmol) were 
added to a solution of 4-bromo-2-chloro-pyridine (0.25 ml, 2.25 mmol) in 5 ml dioxane under a 
nitrogen atomosphere.  The mixture was heated under reflux for 72 h before removal from the 
heat source and the temperature allowed to reach room temperature.  The mixture was filtered 
through 0.5 cm Celite ® and washed with ether (10 ml).  The filtrate was concentrated under re-
duced pressure. The yellow oil obtained was sufficiently purified by chromatography with hex-
anes to yield 0.29 g of  the chloro intermediate,  2-chloro-4-(2-furyl)pyridine (1.61 mmol, 72 %).  
1
HNMR (400 MHz, CDCl3): δ 6.43 (m, 1H, -CH), 6.78 (dd, J = 3.4 Hz, J = 0.6 Hz, 1H, -CH), 
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7.28 (dd, J  = 5.4 Hz, J = 1.4 Hz, 1H, -CH), 7.40 (dd, J = 1.8 Hz,  J = 0.6 Hz, 1H, -CH), 7.44 (dd, 
J = 1.8 Hz, J = 0.6 1H, -CH), 8.22 (dd, J  = 5.4 Hz, J = 0.6 Hz, 1H, -CH).  High resolution ms 
(ESI, positive ion mode): calcd. for C10H7ClO (M + 1)
+
, m/z 180.0216; found m/z 180.0328. (b) 
A mixture of 1-methylpiperazine (1 ml) and 2-chloro-4-(2-furyl)pyridine (0.26 g, 1.69 mmol) 
was stirred overnight at 200 °C in a sealed tube.  The reaction was removed from the heat source 
and allowed to reach room temperature.  Ether (20 ml) was added and the solution concentrated 
under reduced pressure.  The residual brown oil was purified by chromatography eluting with 
dichloromethane/ethanol (100: 1) to yield 0.309 g of 21 (1.27 mmol, 76  %).  
1
HNMR (400 
MHz, CDCl3): δ 2.35 (s, 3H, -CH3), 2.54 (t, J = 5.0 Hz, 2H, -CH2-), 3.62 (t, J = 5.0 Hz, 2H, -
CH2-), 6.49 (q, J = 1.6 Hz, 1H, -CH), 6.78 (m, 1H, -CH), 6.86 (dd, J  = 1.2 Hz, J = 5.2 Hz, 1H, -
CH), 6.39  (s, 1H, -CH), 7.49  (m, 1H, -CH), 8.17 (dd, J = 0.4 Hz, 5.2 Hz, 1H, -CH).  
13
CNMR 
(400 MHz, CDCl3): δ 160.1, 152.3, 148.3, 143.1, 138.8, 111.9, 108.4, 107.9, 100.9, 54.9, 46.2, 
45.2. High resolution ms (ESI, positive ion mode): calcd. for C14H18N3O (M + 1)
+
, m/z 
244.1450; found m/z 244.1459.  A hydrobromide salt was prepared according to general proce-
dure above. Anal. calcd. For C14H17N3O•2HBr: C, 41.51; H, 4.73; N, 10.37; found C, 41.24; H, 
4.78; N, 10.51. 
3.2.2 Preparation of 2,6-Disubstituted Pyridines 
1-(6-Bromopyridin-2-yl)-4-methylpiperazine (22). A mixture of 2,6-dibromo-pyrimidine (1.00 
g, 4.22 mmol) and 1-methylpiperazine (0.16 ml, 1.41 mmol) was stirred in 5 ml dry toluene. The 
solution was treated with tert-butoxide (0.01 g, 0.14 mmol), 
tris(debenzylideneacetone)dipalladium(0) Pd2dba3 (0.01 g, 0.01 mmol), (±)-2,2′-
Bis(diphenylphosphino)-1,1′-binaphthalene BINAP (0.03 g, 0.04 mmol), and 1,8-
Diazabicyclo[5.4.0]undec-7-ene DBU (0.51 ml, 3.44 mmol).  The mixture was heated in a sealed 
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tube for 48 h.  The vessel was removed from heat and the mixture partitioned between ethyl ace-
tate and water.  The aqueous phase was extracted with ethyl acetate (2 x 20 ml).  The organic 
layers were collected and washed with 1.6 M hydrochloric acid (20 ml).  An equivalent volume 
of sodium hydroxide (20 ml) was added to the acidic solution.  Solid sodium bicarbonate was 
added until the solution became basic, approximately pH 8 as measured with pH paper.  The so-
lution was back extracted with ethyl acetate (25 ml) and the organic layers obtained were washed 
with brine.
10
  Concentrated under reduced pressure, the organic layers contained the crude prod-
uct 23 (0.277 g, 1.09 mmol, 77 %).  
1
HNMR (400 MHz, CDCl3): δ 2.16 (s, 3H, -CH3), 2.30 (t, J 
= 4.4 Hz, 2H, -CH2-), 3.37 (t, J = 4.4 Hz, 2H, -CH2-), 6.36 (d, J = 4.0 Hz, 1H, -CH), 6.56 (d, J = 
4.0 Hz, 1H, -CH), 7.11 (m, 1H, -CH).  
13
CNMR (400 MHz, CDCl3): 160.1, 152.3, 148.3, 143.1, 
138.8, 111.9, 108.4, 107.9, 100.9, 54.9, 46.2, 45.2. High resolution ms (ESI, positive ion mode): 
calcd. for C10H14N3 (M + 1)
+
, m/z 256.0449; found m/z 256.0444. 
1-Methyl-4-(6-(3-thienyl)pyridine-2-yl)piperazine (23).  Thiophene-3-boronic acid (0.20 g, 
1.54 mmol), Pd(dppf)2Cl2 (0.03 g, 0.04 mmol), potassium phosphate dibasic (0.47 g, 2.69 mmol) 
were combined with 22 (0.14 g, 0.54 mmol) in 5 ml of 1,4 dioxane under nitrogen gas.  The reac-
tion was heated under reflux for 72 h before removal from the heat source.  The mixture reached 
room temperature, after which time the mixture was filtered through 0.5 cm Celite ® and washed 
with ether (20 ml).  The filtrate was concentrated under reduced pressure.  The resulting brown 
oil was purified by chromatography with dichloromethane/methanol (50:1) to yield 0.059 g of 23 
(0.23 mmol, 42 %).  
1
HNMR (400 MHz, CDCl3): δ 2.35 (s, 3H, -CH3), 2.53 (t, J = 5.0 Hz, 2H, -
CH2-), 3.64 (t, J = 5.0 Hz, 2H, -CH2-), 6.54 (d, J = 4.0 Hz, 1H, -CH), 6.97 (d, J = 4.0 Hz, 1H, -
CH), 7.33 (m, 1H, -CH), 7.49 (t, 4 Hz, 1H, -CH), 7.63 (m, 1H, -CH), 7.86 (m, 1H, -CH). 
13
CNMR (400 MHz, CDCl3): δ 159.0, 154.4, 143.0, 138.2, 126.4, 125.7, 123.0, 109.7, 105.2, 
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55.0, 46.3, 45.1.  Anal. calcd. For C14H17N3S•2HBr•H2O: C, 39.09; H, 4.69; N, 9.77; found C, 
39.11; H, 4.79; N, 9.90. 
1-(6-(3-Furyl)pyridine-2-yl)-4-methylpiperazine (24).  Furan-3-boronic acid (0.06 g, 0.53 
mmol), Pd(dppf)2Cl2 (0.01 g, 0.01 mmol), and potassium phosphate dibasic (0.16 g, 0.92 mmol) 
were added to 22 (0.07 g, 0.26 mmol) stirring in 5 ml of 1,4 dioxane under nitrogen pressure.  
The mixture was heated to reflux for 96 h.  The reaction vessel was removed from the heat 
source and allowed to reach room temperature before filtration through 0.5 cm of Celite ®.  The 
filtrate was concentrated under reduced pressure and purified by chromatography eluting with 
hexanes to yield 0.050 g of 25 (0.21 mmol, 80 %).  
1
HNMR (400 MHz, CDCl3): δ 2.37 (s, 3H, -
CH3), 2.57 (t, J = 5.0 Hz, 2H,    -CH2-), 3.64 (t, J = 5.0 Hz, 2H, -CH2-), 6.54 (m, 1H, -CH), 6.85 
(m, 1H, -CH), 7.30 (m, 1H, -CH), 7.49 (m, 1H, -CH), 7.99 (s, 1H, -CH).  
13
CNMR (400 MHz, 
CDCl3): δ 159.1, 149.75, 143.4, 141.1, 138.0, δ 127.7, 109.5, 108.8, 105.0, 55.0, 54.9, 46.3, 45.5, 
45.0.  High resolution ms (ESI, positive ion mode): calcd. for C14H18N3O (M + 1)
+
, m/z 
244.1461; found m/z 244.1450.  Anal. calcd. For C14H17N3O•2HBr•2H2O: C, 38.12; H, 5.25; N, 
9.52; found C, 38.23; H, 5.33; N, 9.72. 
1-(6-(2-Furyl)pyridin-2-yl)-4-methylpiperazine (25).  Furan-3-boronic acid (0.03 g, 0.27 
mmol) and Pd(PPh3)4 (0.02 g, 0.01 mmol) were added to 22 stirring in dimethylformamide (4 
ml).  Potassium carbonate (0.13 g, 0.96 mmol) dissolved in 1 ml water was added and the reac-
tion mixture refluxed 72 h.  The reaction vessel was removed from the heat source and allowed 
to reach room temperature before filtration through 0.5 cm Celite ®.  The yellow filtrate was par-
titioned between ethyl acetate and water (2 x 20 ml).  The organic layers were combined, dried 
over magnesium, and filtered.  The filtrate was then concentrated under reduced pressure.  The 
brown oil was purified by chromatography eluting with dichloromethane/ethanol (26: 1) to yield 
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0.025 g of 26 (0.102 mmol, 38 %). 
1
HNMR (400 MHz, CDCl3): δ 2.34 (s, 3H, -CH3), 2.52 (t, J 
= 5.0 Hz, 4H, -CH2-), 3.61 (t, J = 5.0 Hz, 4H, -CH2-), 6.57 (d, J = 3.6  Hz, 1H, -CH), 6.77 (d, J = 
3.6 Hz, 1H, -CH), 6.85 (d, J = 5.2 Hz, 1H, -CH), 6.92 (s, 1H, -CH), 7.48 (d, J = 1.6 Hz, 1H, -
CH), 8.17 (d, J = 5.2 Hz, 1H, -CH).  
13
CNMR (400 MHz, CDCl3): δ 160.1, 152.3, 148.3, 143.1, 
138.8, 111.9, 108.4, 107.9, 100.9, 54.9, 46.2, 45.2. Anal. calcd. For C14H21N3O •2HBr,2H2O: C, 
38.29; H, 4.82; N, 9.57; found C, 37.94; H, 5.02; N, 9.54. 
3.3 Preparation of Hydrobromic Salts 
All salts were prepared using 48% 9N HBr solution in 0.9:1 molar ratio with the free base 
compounds of interest. 
4 CONCLUSIONS 
Addition at the vinyl moiety of 2-chloropyrimidine has been achieved with various nuc-
leophiles.  For stronger nucleophiles, substitution occurs preferentially at the chloro position ra-
ther than addition across the vinyl group.  Addition of a heteroaryl compound to the 4-bromo-2-
chloropyridine ring is achieved via Suzuki coupling.  Substitution of the chlorine atom with 1-
methylpiperazine is achieved under high heating conditions.  Mono-substitution at bromine of 
2,6-dibromopyridine was accomplished through the use of a divalent palladium catalyst. 
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